

PROMISING PRACTICES FOR PROMOTING UTILIZATION OF COVID-19 MONOCLONAL ANTIBODY TREATMENTS

The ability to provide **home infusion** to patients quickly after a positive COVID-19 test result represents a unique opportunity to reach home-bound, travel-limited, or rural patients in need of COVID-19 monoclonal antibody (mAb) treatment. Here, we outline emerging promising practices, example stakeholder antibody treatment efforts, and shared resources to further support home infusion of antibody treatments at scale.

CRITICAL STEPS

Streamline the care process

- [Partnership](#) with providers in high-risk settings or underserved communities
- Timely scheduling for referred patients

Educate participants in the care process

- Assure that community [providers](#) and [patients](#) are aware of infusion availability (via web resources, state supports, etc.)

Expand footprint to increase access

- Assure that infusion capacity is adequate to meet current and projected local needs (state/local public health and regional planning)

Ensure adequate payment

- Infusion services are generally reimbursed at the same rate regardless of setting, despite a higher cost structure per patient in some settings. Higher reimbursement level for home infusion is needed to support this pathway.
- Some high-risk facilities, state/local governments, and payers may arrange advance payment contracts (e.g., advance commitment for a certain volume of services per month)

INNOVATIVE EXAMPLES & RESOURCES

Streamline the care process and expand footprint to increase access

- Through [ASPR's SPEED program](#), members of the National Home Infusion Association (NHIA) are deployed to provide home infusions, primarily in long-term care (LTC) settings lacking staff trained to provide infusions. COVID-19 monoclonal antibody treatment can also be obtained through [ASPR's direct ordering process](#).
- Coram, CVS's home-based infusion service, is conducting a [pilot](#) with HHS in which it provides access to antibody treatments in seven metro areas around the country.

Educate participants in care process

- ASPR has released a [Monoclonal Antibody Therapeutics Digital Toolkit](#) with educational material about treatment options tailored for various social media platforms and a variety of patient demographics to increase patient awareness of treatment availability and eligibility criteria.
- NHIA provides a [list and map](#) of providers participating in their monoclonal antibody pilot program as well as resources including one for [billing and coding](#).
- The National Infusion Center Association (NICA) has extensive sets of resources on their website targeted at antibody infusion [providers](#), [prescribers](#), and [patients](#).
- HHS has a [locator tool](#) displaying locations that have received COVID-19 monoclonal antibody allocations.